Indication
Brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency
Loading your page…
Loading your page…
Neuronal Ceroid-Lipofuscinoses
Marketing Authorisation Holder: BioMarin International Limited
EMA Authorisation: 30/05/2017
INN: cerliponase alfa
AI Drug & Interaction Analysis
Free account required
Ask Osler about Brineura: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.